Search Results

CAR T-cell Therapy and Transplant: Individualized Treatment Choices and Sequencing for Optimal Outcomes

* required.Breakfast Symposium will be held during the Oncology Nursing Society's (ONS) 51st Annual Congress. Participants must be registered for the …

Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment

In collaboration with AVEO Oncology, an LG Chem company, (“AVEO”) the new Beat AML is evaluating ficlatuzumab, a monoclonal antibody targeting hepato…

Nearly 60% of Blood Cancer Patients Covered By Medicare Delay or Forgo Treatment

View full multimedia release here. Highlights of Milliman Study on Medicare treatment costs…

Hematopoietic Cell Transplantation as Treatment for Blood Cancers: The Team Approach - For Nurses

For Nurses and Advanced Practice Providers

Biomarker and Risk Tailored Treatment to Improve Outcomes in Diffuse Large B-cell Lymphoma

Improving survival for patients with diffuse large lymphoma requires tailoring treatment to lymphoma genetic heterogeneity, addressing minimal residu…

Newly FDA-approved Treatment Enhances Survival for Children and Adults with 2 Blood Cancer Types

The FDA approval will benefit children and adults with acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). RYE BROOK, N.Y., January , …

Newly FDA-approved Treatment Enhances Survival for Children and Adults with 2 Blood Cancer Types

The FDA approval will benefit children and adults with acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). RYE BROOK, N.Y., January , …

Early Detection and Intervention in Smoldering Multiple Myeloma: population-based screening and treatment; Edit-SMM

We build on the success from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) study, where over , consented to a nationwide screeni…

CD70-directed CAR T-cell therapy for the treatment of relapsed/refractory pediatric AML

In this project, we will test an innovative therapy called CAR therapy for children with a type of cancer called AML. In the laboratory, we have iden…

Interrogating T-cell apoptotic priming to improve CAR-T persistence in treatment of lymphoid malignancies

cells are made from a patient’s own immune cells, altered so that they specifically recognize and kill the patient’s cancer cells. They are effective …

Suggested Reading - 100 Questions & Answers About Cancer Symptoms and Cancer Treatment Side Effects

Myeloma Awareness Month-Research Highlight: Changing the Landscape of Treatment for Multiple Myeloma (Part 2)

For the final installment of this series focusing on myeloma research, we will review advances in immunotherapies for myeloma. The most exciting curre…

European Commission Approves ELZONRIS for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

FLORENCE, January , – The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, announced today that the European Commissi…

Development of BET protein bromodomain inhibitors for the treatment of patients with hematologic malignancies

In July , LLS began its partnership with Constellation to support three Phase clinical trials for blood cancer patients and the partnership led to t…

Latest FDA Approval in Multiple Myeloma May Reduce Treatment Costs, Frequency and Side Effects

The FDA’s approval of a less frequent treatment regimen in patients with multiple myeloma highlights a trend of making treatments easier for blood can…

Blood Cancer 101: The Basics on Disease, Treatment, and the Role of the HCP

This activity is intended for oncology social workers, psychologists, nurses, and other healthcare professionals involved in the care of patients with…

Leading Treatment for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Now Available in Tablet Form

WASHINGTON, (June , ) – The U.S. Food and Drug Administration has approved a new tablet formulation of zanubrutinib (Brukinsa®) which is used to treat…

LLS Applauds FDA Approval of New Treatment Option for Pediatric Patients with Hodgkin Lymphoma

The U.S. Food and Drug Administration (FDA) yesterday approved brentuximab vedotin (Adcetris®) in combination with standard chemotherapy in children …

Blood Cancer 101: The Basics on Disease, Treatment, and the Role of the HCP

This activity is intended for oncology social workers, psychologists, nurses, and other healthcare professionals involved in the care of patients with…

Insured Cancer Patients Continue to Face Barriers To Medically Necessary Treatment, New Report Warns

The new report published by The Leukemia & Lymphoma Society and Manatt Health offers concrete policy solutions.

FDA Approves New Treatment Option for Patients with Relapsed or Refractory Large B-Cell Lymphoma

RYE BROOK, N.Y., August , - The U.S. Food and Drug Administration (FDA) approved loncastuximab (ZYNLONTA) to treat adult patients with relapsed or r…

Blood Cancer 101: The Basics on Disease, Treatment, and the Role of the HCP

Cobomarsen Received Orphan Drug Designation from the U.S. FDA for the Treatment of T-cell Lymphoma

BOULDER, Colo., July , - miRagen Therapeutics, Inc. (NASDAQ: MGEN), a biopharmaceutical company focused on the discovery and development of therapi…

BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma

Lund, Sweden – March , – BioInvent International AB (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and…

Another CAR T -Cell Therapy Approved for Earlier Treatment of the Most Common Type of Lymphoma

The U.S. Food and Drug Administration (FDA) today approved CAR lisocabtagene maraleucel (Breyanzi®) for treatment of adults with large lymphoma (LBC…